Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.
about
Pharmacokinetic interaction between domperidone and ketoconazole leads to QT prolongation in healthy volunteers: a randomized, placebo-controlled, double-blind, crossover studyAssociation between the number of coadministered P-glycoprotein inhibitors and serum digoxin levels in patients on therapeutic drug monitoringEffects of ketoconazole on the biodistribution and metabolism of [11C]loperamide and [11C]N-desmethyl-loperamide in wild-type and P-gp knockout mice.Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safetyCellular localization and functional significance of CYP3A4 in the human epileptic brain.Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity.Oral contraception does not alter single dose saquinavir pharmacokinetics in womenThe ABC transporters MDR1 and MRP2: multiple functions in disposition of xenobiotics and drug resistance.Improving cancer chemotherapy with modulators of ABC drug transporters.Pharmacogenetics of antiparkinsonian drug treatment: a systematic review.Influence of solute carriers on the pharmacokinetics of CYP3A4 probes.Pharmacogenomics of CYP3A: considerations for HIV treatment.Intersection of the Roles of Cytochrome P450 Enzymes with Xenobiotic and Endogenous Substrates: Relevance to Toxicity and Drug Interactions.Update information on drug metabolism systems--2009, part I.Future directions of stroke prevention in atrial fibrillation: the potential impact of novel anticoagulants and stroke risk stratification.Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics.Secondary Metabolites from Plants Inhibiting ABC Transporters and Reversing Resistance of Cancer Cells and Microbes to Cytotoxic and Antimicrobial Agents.New avenues for anticoagulation in atrial fibrillation.Pharmacology of the new target-specific oral anticoagulants.Experimental models for predicting drug absorption and metabolism.Potential food-drug interactions in patients with rheumatoid arthritis.Phase 0 and phase III transport in various organs: combined concept of phases in xenobiotic transport and metabolism.Pregnane X Receptor and P-glycoprotein: a connexion for Alzheimer's disease management.Pharmacokinetic herb-drug interactions with traditional Chinese medicine: progress, causes of conflicting results and suggestions for future research.Identification of cellular and molecular factors determining the response of cancer cells to six ergot alkaloids.Renal Drug Transporters and Drug Interactions.Natural Products as Alternative Choices for P-Glycoprotein (P-gp) Inhibition.Pattern of P450 expression at the human blood-brain barrier: roles of epileptic condition and laminar flowCooperation between prokaryotic (Lde) and eukaryotic (MRP) efflux transporters in J774 macrophages infected with Listeria monocytogenes: studies with ciprofloxacin and moxifloxacin.Pharmacokinetic evaluation of oral itraconazole for antifungal prophylaxis in children.Inhibitory Potential of Antifungal Drugs on ATP-Binding Cassette Transporters P-Glycoprotein, MRP1 to MRP5, BCRP, and BSEP.ANMCO Position Paper: the use of non-vitamin K dependent new oral anticoagulant(s) in pulmonary embolism therapy and prevention.Permeability of ergot alkaloids across the blood-brain barrier in vitro and influence on the barrier integrity.Contribution of ABCC4-mediated gastric transport to the absorption and efficacy of dasatinib.New anticoagulants in atrial fibrillation: an update for clinicians.Novel pepper extract for enhanced P-glycoprotein inhibition.Pulmonary and hepatic toxicity due to nitrofurantoin and fluconazole treatment.Paradoxical cyclosporine A requirements in pediatric renal transplants receiving high-dose steroids.Machine learning-, rule- and pharmacophore-based classification on the inhibition of P-glycoprotein and NorA.In vitro inhibition of CYP3A4 metabolism and P-glycoprotein-mediated transport by trade herbal products.
P2860
Q24608623-F50C8627-A7F7-4864-AE90-DE253BFFB513Q24799859-781EDCCD-F96C-4730-B31A-8DCAEB37A2CFQ33761780-16DDD0A7-91EA-40DD-86A2-52D3178B2D2AQ34123368-5CE7639C-8F18-41B9-8328-1CED63F03AD8Q34669448-8658CB07-2EFD-4D3A-85FD-C04DA7C5E42AQ34990717-D080020B-53B3-4C05-8A2A-79EC158DF50DQ35825971-7F0AF274-BEF9-4318-8BE8-C161C7D967E3Q35956193-E5D812A9-7196-4F31-A3B2-65E52B3BF49CQ36108251-42FA427E-B923-4BA0-A84D-7F694FFC7EACQ36730631-F2AE2C0E-E59E-4F3B-B381-E7F011B78F4BQ37176032-0E29EB47-B218-411B-8B2F-F4B3ED6CF398Q37419542-53E03BB6-488D-4FF1-AD34-7143A6E5F72BQ37627001-8546075F-A6E0-4F38-97A1-A43E6D75875CQ37716030-9F889FE5-AB0C-4102-A5B0-F637E647D8F6Q37822915-1A053603-DB47-47BF-A7C6-0C8045C97C9BQ37904672-F74F6DE6-1B87-4D8C-8186-7BDB5DF5EAF7Q38005689-A21E50C0-FFF3-4796-B088-6A9558403FD8Q38065063-78FFD5F7-402E-48D8-8C51-E0BADF87DE75Q38104314-090EDB0A-BA1D-42FF-A184-E4CF9A0159E8Q38107970-A17FB7A7-10AD-4EFB-A62A-E2A8ACAF4E22Q38115004-4BB14309-20E4-4770-BA0E-648D9D1201ECQ38183877-5E389A72-C7DE-4774-81B4-B5E2052A1282Q38248506-F3FD2EEA-CC30-4055-A1F8-F4BC8EF2AFD9Q38750365-096C5FCB-C68F-4697-8707-AF3768BED96BQ38945474-7D7E1D1A-57DD-4560-8C22-EC9EA0F106E5Q39140289-8369889B-B7E8-4C53-B6B6-842E7DC80FA3Q39354491-347EBFBD-A9FB-40CD-B0C0-827EF873B1FDQ39752034-942E0848-750C-4ED2-B1AA-46076265A883Q39968960-8AAD03B4-A241-45B5-9D9C-667B40DB71F4Q40119390-9F59DEF6-ADA0-47AE-A6F2-8DDEC23445ADQ40746038-D2486B19-4CF6-4871-A63B-E0703A63375CQ41118456-8BDC8A59-F6D7-469C-B2D5-11AABE9FAB5BQ41353684-88B50F3F-D953-4488-AB25-5295A6F304FAQ41763725-FE645148-47BF-45C7-9C4B-CBA625D194FFQ42385248-F6857358-6825-42F7-B4AB-3BFAB77D99E9Q43287004-EB873A93-4BEB-4B8F-A100-35795AC416D8Q44765805-A114176B-D102-4AA2-843D-193331987DCAQ45221738-5A68B0A3-35E9-4F09-B69C-207CED9275B8Q45950000-413802AC-59B0-461C-AF41-96D365297BF5Q46709627-A546878A-A60E-4E04-8441-F24830819159
P2860
Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.
@en
type
label
Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.
@en
prefLabel
Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.
@en
P2093
P356
P1476
Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.
@en
P2093
Erin G Schuetz
John D Schuetz
Katryn Furuya
Kazuto Yasuda
Lu-Bin Lan
P304
P356
10.1124/JPET.102.037549
P407
P577
2002-10-01T00:00:00Z